Ascenion’s portfolio company T-knife receives $110 million for the development of innovative T-cell therapies in cancer
Initiation of the IMAGE1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in Q4 2021
05-Aug-2021 -
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with ...
cancer therapeutics
T-cell receptors